Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a significant move in the pharmaceutical industry by acquiring 89bio for $3.5 billion, with a contingent value right of $6 per share. The acquisition includes pegozafermin, an analog in late-stage development for metabolic dysfunction-associated steatohepatitis. Meanwhile, former CDC director Susan Monarez spoke to the Senate about her firing, alleging that Health Secretary Robert F. Kennedy Jr. accused CDC employees of "killing children." In other news, Roivant and Pfizer's therapy shows promise in a rare inflammatory condition, BMS and Novo Nordisk have announced layoffs in New Jersey, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. Additionally, Lexicon has backed phase III decision for a non-opioid pain medication, and Rosnilimab shows promise as a potential next-generation treatment for rheumatoid arthritis. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies like Arsenal and X4 laying off staff to cut costs.The FDA is cracking down on pharmaceutical advertisements in a new regulatory initiative, targeting loopholes in direct-to-consumer ads. Experts believe the FDA is focusing on the wrong issues and should instead address the lack of regulations for compounder drug ads. Akeso, a biotech company in China, has seen success under CEO Michelle Xia's leadership. Other news in the pharmaceutical industry includes the rise of predictive care powered by consumers and AI, ongoing prescriptions of Sarepta's DMD gene therapy despite safety concerns, and companies like Sanofi pulling back from the UK market. Pharma companies are facing challenges in navigating uncertain times amidst layoffs and regulatory crackdowns. Stay tuned for more updates on the latest developments in the industry.

Support the show